Skip to main content
About
Contact
Subscribe
e-Edition
Make Home Page
Sign Up
Log In
Dashboard
Logout
My Account
Dashboard
Profile
Saved items
Logout
Facebook
Twitter
Toggle navigation
Site search
Search
Home
Contact Us
Advertise
Subscription Services
Promote Your Event
Submission Forms
News
Local News
National
World
Archives
Sports
Local Sports
National Sports
Business
Local Business
National Business
Technology
Markets & Stocks
Opinion
Columns
Editorials
Letters To The Editor
Polls
Thumbs
A & E
Local Entertainment
Art Scene
Music Scene
Theatre Scene
Book Reviews
Movie Reviews
TV Listings
Local Events
What To Do
Life
Health
Travel
Oddities
Community Directory
Community Service
Rescue Me
Other
Specials
Spring Home & Garden Show
Home & Realty
Outdoor Guide
Women
Spring on the Road
Spring Wellness
Premier Home Stylle Tour 2024
Classifieds
Place Ad
Careers
Tenders
Weather
Obituaries
Parcel Pickup
2024 Readersâ Choice
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
AbbVie
(NY:
ABBV
)
193.62
UNCHANGED
Streaming Delayed Price
Updated: 7:00 PM EDT, Sep 19, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about AbbVie
< Previous
1
2
3
4
5
6
7
Next >
AbbVie and Immunome Announce Strategic Collaboration to Discover Multiple Novel Oncology Targets
January 06, 2023
From
Immunome, Inc.
Via
Business Wire
Harpoon Therapeutics Remains Volatile After Promising News
December 14, 2022
Harpoon Therapeutics offers an example of biotech's volatility. The stock advanced as much as 191% intraday Monday before settling down to a gain of 22.61%.
Via
MarketBeat
MarketBeat: Week in Review 11/14 – 11/18
November 19, 2022
This week, investors digested negative news from the retail sector and the Fed and next week's abbreviated trading week won't bring much new news.
Via
MarketBeat
Topics
Economy
Workforce
Exposures
Economy
Interest Rates
Layoff
Optimism Building for Advancing Pancreatic Cancer Treatment Therapies
December 01, 2022
EQNX::TICKER_START (NASDAQ:ONCY),(NYSE:RCUS),(NASDAQ:AZN),(NYSE:BMY),(NYSE:ABBV) EQNX::TICKER_END
Via
FinancialNewsMedia
Exposures
Product Safety
Can AbbVie Grow Revenue When Humira Biosimilars Hit The Market?
November 16, 2022
Shares of AbbVie have been in rally mode since late October. The company has newer drugs whose revenue could make up for declines due to Humira's patent expiry.
Via
MarketBeat
Topics
Intellectual Property
Exposures
Intellectual Property
MarketBeat: Week in Review 10/31-11/4
November 05, 2022
You can count on MarketBeat to point you towards the stocks that are good opportunities. Here are some of the most popular articles from this week
Via
MarketBeat
Topics
Economy
Exposures
Interest Rates
One in Five Americans Who Have Been Infected With the Virus Said to Have Long COVID
November 17, 2022
Palm Beach, FL – November 17, 2022 – FinancialNewsMedia.com News Commentary – Since the beginning of the pandemic, the critical effort of researchers is to understand how coronavirus damages the body....
Via
FinancialNewsMedia
Exposures
COVID-19
Why is AbbVie Stock Falling, but Still Good Long-Term?
October 31, 2022
Why is AbbVie stock dropping today but still a solid investment? Its solid base, robust pipeline and dividend support a long position in ABBV stock.
Via
MarketBeat
Topics
Intellectual Property
Exposures
Intellectual Property
As Sales of Botox and Juvederm Begin to Stall, the Abbvie Stock Price Drops
October 28, 2022
AbbVie Inc (NYSE:ABBV) AbbVie Inc (NYSE:ABBV) quarterly sales were below Wall Street’s expectations on Friday, primarily due to lower-than-anticipated income from its popular cosmetic filler Juvederm...
Via
PressReach
Topics
Economy
Exposures
Economy
Interest Rates
Merck Nears Breakout Point After October Surprise Good News
October 19, 2022
Dow component Merck is within 2% of an all-time high after rallying 7.30% in the past month. It got a boost from news about two new treatments.
Via
MarketBeat
Topics
Stocks
Exposures
US Equities
Does J&J Have Enough Alpha to Be a Solid Low Beta Stock?
October 19, 2022
JNJ stock is seen as a defensive play which has typically done well in bear markets. But there is one issue that makes longer-term forecasts uncertain
Via
MarketBeat
Topics
Economy
Exposures
Economy
Mainz Biomed (MYNZ) nominates two notable leaders in key areas of the diagnostics field to its Board of Directors
September 29, 2022
Via
AB Newswire
CannabisNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Appoints New Board Member
September 02, 2022
Via
Investor Brand Network
Topics
Intellectual Property
Exposures
Intellectual Property
Product Safety
CannabisNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Appoints New Board Member
September 02, 2022
Via
CannabisNewsWire
Topics
Intellectual Property
Exposures
Intellectual Property
Product Safety
Should AbbVie Inc. Have a Place in Your Dividend Portfolio?
August 26, 2022
Does AbbVie Inc. fit well into your portfolio? We'll take a look at several factors before you decide whether investing in shares makes sense for your needs.
Via
MarketBeat
ABBVIE INVESTIGATION CONTINUED by Former Louisiana Attorney General: Kahn Swick & Foti, LLC Continues to Investigate the Officers and Directors of AbbVie Inc. - ABBV
August 12, 2022
From
Kahn Swick & Foti, LLC
Via
Business Wire
NYSE:ABBV Long Term Shareholder Notice: Investigation of Potential Wrongdoing at AbbVie Inc.
August 10, 2022
San Diego, CA -- (SBWIRE) -- 08/10/2022 -- Certain directors of AbbVie Inc. are under investigation concerning potential breaches of fiduciary duties.
Via
SBWire
Are Medtronic And Intuitive Surgical Poised For Big Growth?
August 09, 2022
Health care is one of the better-performing sectors in 2022, with medical gear makers Medtronic and Intuitive Surgical outpacing the broader industry recently.
Via
MarketBeat
Topics
ETFs
Exposures
COVID-19
Two Appealing Biotech Stocks for Two Distinct investors
August 08, 2022
Investing in biotech stocks carries both risk and reward. This article highlights two biotech companies that may appeal to specific investing styles
Via
MarketBeat
Topics
Intellectual Property
Exposures
COVID-19
Intellectual Property
3 Pharma Stocks' Post-Earnings Price Moves
August 04, 2022
The health care sector is participating in the S&P's nascent rally, but pharmaceuticals AbbVie, Merck and Pfizer are holding up well relative to the market.
Via
MarketBeat
Topics
ETFs
Stocks
Exposures
US Equities
MarketBeat: Week in Review 7/25 – 7/29
July 30, 2022
The markets are rallying as big tech earnings are lifting investors' spirits. Here are some of the stocks our analysts were looking at this week.
Via
MarketBeat
Topics
Artificial Intelligence
Economy
Exposures
Artificial Intelligence
Economy
Interest Rates
Should You Buy AbbVie Ahead Of Earnings?
July 28, 2022
AbbVie (NYSE: ABBV) is due to announce its earnings over the next couple of days. Some investors are considering buying it in advance, but it is worth the investment?
Via
MarketBeat
MarketBeat: Week in Review 7/18 – 7/22
July 22, 2022
Investors should be careful not to read too much into this week's rally. Next week will bring the Fed's decision on interest rates and key earnings reports from the tech sector. Both could cause...
Via
MarketBeat
Topics
Economy
Exposures
Economy
Interest Rates
Supply Chain
A Dose of AbbVie Stock Can Help Your Bear Market Portfolio
July 20, 2022
AbbVie (NYSE: ABBV) is a conventional stock for unconventional times. And that’s exactly why it makes sense to add or hold in your bear market portfolio.
Via
MarketBeat
Topics
Earnings
Economy
Exposures
Financial
Interest Rates
Genmab Announces That AbbVie Will Submit Marketing Authorization Application to European Medicines Agency for Epcoritamab (DuoBody®-CD3xCD20) for the Treatment of Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL)
July 18, 2022
From
Genmab A/S
Via
Business Wire
ABBVIE INVESTIGATION CONTINUED by Former Louisiana Attorney General: Kahn Swick & Foti, LLC Continues to Investigate the Officers and Directors of AbbVie Inc. - ABBV
July 15, 2022
From
Kahn Swick & Foti, LLC
Via
Business Wire
NYSE:ABBV Long Term Shareholder Alert: Investigation of Potential Wrongdoing at AbbVie Inc.
July 08, 2022
San Diego, CA -- (SBWIRE) -- 07/08/2022 -- Certain directors of AbbVie Inc. are under investigation over possible breaches of fiduciary duties.
Via
SBWire
ABBVIE INVESTIGATION INITIATED by Former Louisiana Attorney General: Kahn Swick & Foti, LLC Investigates the Officers and Directors of AbbVie Inc. - ABBV
June 24, 2022
From
Kahn Swick & Foti, LLC
Via
Business Wire
6 Best Dividend Stocks of All Time
June 21, 2022
When you're ready to say, "Tag, you're it!" and let dividend stocks take over your portfolio, you naturally want to gravitate toward A+ companies. Luckily, you don't need to look much further than...
Via
MarketBeat
Topics
Economy
Exposures
Interest Rates
BioMedNewsBreaks – Odyssey Health Inc.’s (ODYY) Novel Drug Candidate Represents a Valuable Asset
June 15, 2022
Via
Investor Brand Network
< Previous
1
2
3
4
5
6
7
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.